Pfizer's (PFE) palbociclib, in combination with trastuzumab, with or without pertuzumab, and endocrine therapy has received the US Food and Drug Administration's approval as a maintenance treatment for adults with HR-positive, HER-2 positive locally advanced or metastatic breast cancer, the regulator said Wednesday.
The recommended dosage for the drug is 125mg orally once a day for 21 days, followed by seven days off treatment to complete a 28-day cycle.
Palbociclib received breakthrough therapy designation, the FDA said.
Price: $24.27, Change: $-0.45, Percent Change: -1.84%